Cryptococcus neoformans var. grubii Franzot et al.
商品貨號
B168997
Deposited As
Cryptococcus neoformans (Sanfelice) Vuillemin
Strain Designations
7588/9.854 MCV 3 [NCCLS 88]
Application
susceptibility testing
susceptibility testing antifungal agents
Biomedical Research and Development Material
Emerging infectious disease research
Biosafety Level
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Product Format
freeze-dried
Storage Conditions
Frozen: -80°C or colder Freeze-Dried: 2°C to 8°C Live Culture: See Propagation Section
Type Strain
no
Preceptrol®
no
Comments
Synergistic effect of combination of fluconazole and flucytosine
This yeast was re-identified as Cryptococcus neoformans var. grubii based on the multigene DNA sequence comparison.
Medium
ATCC® Medium 28: Emmons' modification of Sabouraud's agar
ATCC® Medium 200: YM agar or YM broth
ATCC® Medium 323: Malt agar medium
Espinel-Ingroff A, et al. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 30: 3138-3145, 1992. PubMed: 1452697
Nguyen MH, et al. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39: 1691-1695, 1995. PubMed: 7486902
Medical microbiology--Susceptibility testing of microbial pathogens to antimicrobial agents -- Part 84: Microdilution; Special requirements for testing of fungi against antifungal agents. Berlin, Germany:Deutsches Institut fur Normung;DIN DIN 58940-84: 2002, 2002
